Status:
COMPLETED
Multicenter Study Evaluating the Efficacy of an Intervention Aimed At Reducing the Length of Stay After Transfemoral Transcatheter Aortic Valve Implantation
Lead Sponsor:
University Hospital, Rouen
Conditions:
Aortic Valve Stenosis
Cardiovascular Diseases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Since the first implantation of a percutaneous aortic bioprosthesis (TAVI) in 2002 (Cribier et al. Circulation 2002), TAVI occupies an increasing place in the management of aortic stenosis (AR) . Init...
Eligibility Criteria
Inclusion
- Patient over 18 years of age;
- Patient hospitalized for TF-TAVI
- Patient affiliated or benefiting from a health insurance scheme
- Patient having read and understood the information letter and having signed the consent form.
Exclusion
- Proven pregnant woman (positive urine pregnancy test) or breastfeeding or absence of effective contraception (as defined by the WHO) or postmenopausal woman without confirmation diagnosis obtained (amenorrhea not medically induced for at least 12 months before the initiation visit) ; 1
- Person deprived of their liberty by an administrative or judicial decision or person placed under the protection of justice / guardianship or curatorship
- History of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participating in the protocol or preventing him from giving his informed consent
Key Trial Info
Start Date :
December 16 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 9 2022
Estimated Enrollment :
1842 Patients enrolled
Trial Details
Trial ID
NCT04503655
Start Date
December 16 2020
End Date
February 9 2022
Last Update
December 9 2024
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU d'Amiens
Amiens, France
2
CHU d'Angers
Angers, France
3
CHU de Bordeaux
Bordeaux, France
4
CHU de Brest
Brest, France